Many prescriptions drugs can cause alternate problems when trying to cure the original issue – a huge, well-known issue of prescription drugs. Now, a new study published in the journal Clinical Epidemiology adds to this notion, finding that statins, commonly prescribed to lower cholesterol, are associated with an increased risk of thyroid cancer in women.
Researchers suggest that statins, when in the presence of a female dominant hormone called – a form of estrogen, become ineffective at exhibiting long term ‘cancer-protective properties’ as studies suggest they do. In fact, the drugs are linked to an increased chance of thyroid cancer in women.
Yet another study published in the same journal suggests that the problem lies in the immunosuppressive properties of the statin drugs themselves. There are at least 25 different immuno-toxic properties of statins. You can view them all listed under the ‘Adverse Pharmacological Actions’ here.
The stain industry is heavily invested in promoting their drugs. A single pharmaceutical company, Pfizer, has reported sales of $12.4 billion just for statins. So you can understand why they would not want this news to become widely spread, especially since they have promoted statins as anti-cancer agents.
Often, only pro-statin studies are published, as with many other dangerous drugs in the pharmaceutical world. But unfortunately, there is a collection of studies accumulating that statins actually promote cancerous tissue growth. For example:
- Long-term statin use can lead to breast cancer among women between the ages of 55 to 74
- Statins are questionable in preventing prostate cancer.
- This doctor says to run from any cardiologist who prescribes statins to you, “There are new guidelines coming out of the world of cardiology from the American Heart Association and American College of Cardiology proving once and for all that cardiologists are idiots or worse. They simply, en mass, have abandoned their right to call themselves doctors.”
- Statin use doubles risk of breast cancer (again).
- Possible increased risk of kidney cancer with statin use.
The latest study on the potential for statin-induced thyroid cancer is supported by previous scientific research. For instance, a report published in 2000 titled, “Development of thyroid follicular adenoma on simvastatin therapy,” describes a patient who “developed follicular adenoma with prominent Hurthle cell changes after being on simvastatin for three months but not during one year of pravastatin therapy.”
Physiological studies using an animal model have also found statin-induced enhanced growth in the thyroid (thyroid hypertrophy), indicating its potential for contributing to thyroid cancer.
Since this drug has already been linked to over 300 adverse effects, we shouldn’t be surprised that thyroid cancer is yet another to be added to the list.